Hospital chain Tenet to buy Vanguard Health for $1.73 billion
(Reuters) - U.S. hospital operator Tenet Healthcare Corp said on Monday it will buy smaller rival Vanguard Health Systems Inc for $1.73 billion, putting it in a better position to...
Home > Reviews
All Stories
Proxy war raises pressure on Vivus to fatten Qsymia sales
(Reuters) - A proxy war with its top shareholder is building up the pressure on Vivus Inc to quickly ramp up the sales of its diet drug, Qsymia, as skepticism...
Allergan delays drug that would rival Regeneron’s Eylea
(Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea,...
Allergan delays drug that would rival Regeneron’s Eylea
(Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea,...
Slow and steady can win the diet drug race
(Reuters) - Vivus Inc, vying to create the world's first billion-dollar weight-loss pill, is taking a cautious approach to marketing in an attempt to overcome the skepticism, safety concerns and...
Slow and steady can win the diet drug race
(Reuters) - Vivus Inc, vying to create the world's first billion-dollar weight-loss pill, is taking a cautious approach to marketing in an attempt to overcome the skepticism, safety concerns and...
WebMD to cut 14 percent of workforce to reduce expenses
(Reuters) - Health information website WebMD Health Corp said it will cut around 250 jobs, or 14 percent of its workforce, to reduce costs. The company, which had about 1700...
WebMD to cut 14 percent of workforce to reduce expenses
(Reuters) - Health information website WebMD Health Corp said it will cut around 250 jobs, or 14 percent of its workforce, to reduce costs. The company, which had about 1700...
Peregrine says lung cancer trial data erroneous, shares sink
(Reuters) - Peregrine Pharmaceuticals Inc on Monday warned of discrepancies in the results of a mid-stage lung cancer trial, the second time in six months the drugmaker has got into...
Peregrine says lung cancer trial data erroneous, shares sink
(Reuters) - Peregrine Pharmaceuticals Inc on Monday warned of discrepancies in the results of a mid-stage lung cancer trial, the second time in six months the drugmaker has got into...